Business
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking p
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z3roQwquAczfyVwH352A4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47}},"lazy":false},{"type":"text","content":"PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio’s academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.","length":744,"tagName":"p"},{"type":"text","content":"Late-Breaking Oral Presentation:Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy EndpointsPresenter: Katherine Mathews, M.D., Professor of Pediatrics and Neurology at the University of Iowa’s Roy J. and Lucille A. Carver College of MedicineDate: Wednesday, March 11 at 2:00 pm ET","length":339,"tagName":"p"},{"type":"text","content":"Oral Presentation:A High-Throughput Assay for Measuring Ribitol Response Across FKRP VariantsPresenter: Yujiao Yang, Ph.D., Postdoctoral Associate in the Laboratory of Monkol Lek at Yale School of MedicineDate: Wednesday, March 11 at 11:30 am ET","length":248,"tagName":"p"},{"type":"text","content":"Posters:Systematic Literature Review of Clinical Outcomes and Disease Burden in LGMD2I/R9Date: Tuesday, March 10","length":114,"tagName":"p"},{"type":"text","content":"Real-World Insights into LGMD, Including Subtype 2I/R9: Treatment Patterns, Health Care Resource Utilization, and CostsDate: Tuesday, March 10","length":143,"tagName":"p"},{"t...